Kurzrock R - Search Results

1

Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Subbiah V, et al. Among authors: kurzrock r. Mol Cancer Ther. 2012 Nov;11(11):2541-6. doi: 10.1158/1535-7163.MCT-12-0358. Epub 2012 Aug 20. Mol Cancer Ther. 2012. PMID: 22914439 Free PMC article.

2

Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.

Tibes R, Trent J, Kurzrock R. Tibes R, et al. Among authors: kurzrock r. Annu Rev Pharmacol Toxicol. 2005;45:357-84. doi: 10.1146/annurev.pharmtox.45.120403.100124. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822181 Review.

3

Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.

Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Siwak DR, et al. Among authors: kurzrock r. Cancer. 2005 Aug 15;104(4):879-90. doi: 10.1002/cncr.21216. Cancer. 2005. PMID: 16007726 Free article.

4

Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.

Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Khanbolooki S, et al. Among authors: kurzrock r. Mol Cancer Ther. 2006 Sep;5(9):2251-60. doi: 10.1158/1535-7163.MCT-06-0075. Mol Cancer Ther. 2006. PMID: 16985059

5

Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.

Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Gong J, et al. Among authors: kurzrock r. Mol Cancer Ther. 2006 Dec;5(12):2991-3000. doi: 10.1158/1535-7163.MCT-06-0188. Epub 2006 Dec 5. Mol Cancer Ther. 2006. PMID: 17148761

6

Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer.

Li L, Ahmed B, Mehta K, Kurzrock R. Li L, et al. Among authors: kurzrock r. Mol Cancer Ther. 2007 Apr;6(4):1276-82. doi: 10.1158/1535-7163.MCT-06-0556. Mol Cancer Ther. 2007. PMID: 17431105

7

Studies in target-based treatment.

Kurzrock R. Kurzrock R. Mol Cancer Ther. 2007 May;6(5):1477. doi: 10.1158/1535-7163.MCT-07-0255. Epub 2007 May 4. Mol Cancer Ther. 2007. PMID: 17483434

8

Cutaneous castleman's disease responds to anti interleukin-6 treatment.

Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R. Ahmed B, et al. Among authors: kurzrock r. Mol Cancer Ther. 2007 Sep;6(9):2386-90. doi: 10.1158/1535-7163.MCT-07-0256. Epub 2007 Aug 31. Mol Cancer Ther. 2007. PMID: 17766835

9

Studies in target-based treatment.

Kurzrock R. Kurzrock R. Mol Cancer Ther. 2007 Sep;6(9):2385. doi: 10.1158/1535-7163.MCT-06-9S. Epub 2007 Sep 10. Mol Cancer Ther. 2007. PMID: 17846118 No abstract available.

10

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.

Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Sun M, et al. Among authors: kurzrock r. Mol Cancer Ther. 2008 Mar;7(3):464-73. doi: 10.1158/1535-7163.MCT-07-2272. Mol Cancer Ther. 2008. PMID: 18347134

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,014 results

Search Page

Filters